Eli Lilly & Co. is taking a more aggressive legal approach to protecting its weight loss drug portfolio, including retatrutide, which has yet to receive FDA approval.
Vedder Shareholder Melissa Gilmore discussed Eli Lilly’s evolving litigation strategy in the recent Bloomberg Law article, “Eli Lilly Toughens Legal Game Plan Over Next Weight Loss Drug.” Melissa noted that the pharmaceutical company’s experience with prior weight loss drug litigation is helping shape how it crafts its current retratrutide pleadings and claims.
Read the full article here (Subscription required).
